Georgios N. Dalekos, MD; John Hatzis, MD; Epameinondas V. Tsianos, MD
The Editors welcome submissions for possible publication in the Letters section. Authors of letters should:
•Include no more than 300 words of text, three authors, and five references
•Type with double-spacing
•Send three copies of the letter, an authors' form signed by all authors, and a cover letter describing any conflicts of interest related to the contents of the letter.
Letters commenting on an Annals article will be considered if they are received within 6 weeks of the time the article was published. Only some of the letters received can be published. Published letters are edited and may be shortened; tables and figures are included only selectively. Authors will be notified that the letter has been received. If the letter is selected for publication, the author will be notified about 3 weeks before the publication date. Unpublished letters cannot be returned.
Annals welcomes electronically submitted letters.
Dalekos G., Hatzis J., Tsianos E.; Dermatologic Disease during Interferon-α Therapy for Chronic Viral Hepatitis. Ann Intern Med. 1998;128:409-410. doi: 10.7326/0003-4819-128-5-199803010-00015
Download citation file:
Published: Ann Intern Med. 1998;128(5):409-410.
TO THE EDITOR:
Immune-mediated dermatologic disease, particularly lichen planus, may accompany chronic viral hepatitis . Interferon-α therapy may also account for immune-mediated phenomena . Psoriasis and lichen planus have been seen during interferon-α treatment of cancer . Despite case reports of lichen planus during interferon-α therapy, a large Japanese study  found no immune-mediated dermatologic disease, and a retrospective Italian study  found a prevalence of 0.12%.
to gain full access to the content and tools.
Learn more about subscription options.
Register Now for a free account.
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only